SCHEMBL1338929

SCHEMBL1338929

CCOC(=O)c1cc(-c2ccc3c(c2)c2cc(-c4ccc(Cl)cc4Cl)c(=O)n(C)c2n3C)nn1C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 3/20 0.39
▸ TSHR P16473 3/20 0.39
▸ SMN1; SMN2 Q16637 3/20 0.39
▸ MAPT P10636 2/20 0.39
▸ NPC1 O15118 2/20 0.39
▸ RAB9A P51151 2/20 0.39
▸ HSD17B10 Q99714 2/20 0.39
▸ FAAH O00519 2/20 0.39
▸ LMNA P02545 3/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ GABRA2 P47869 5/20 0.37
▸ GABRB2 P47870 5/20 0.37
▸ MAPK8 P45983 1/20 0.37
▸ MAPK9 P45984 1/20 0.37
▸ MAPK10 P53779 1/20 0.37
▸ CNR1 P21554 2/20 0.37
▸ CNR2 P34972 2/20 0.37
▸ KDM4E B2RXH2 2/20 0.36
▸ ALDH1A1 P00352 2/20 0.36
▸ TDP1 Q9NUW8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1337011 0.84 FAAH (0.41) POLBSMN1; SMN2MAPTNPC1RAB9A
SCHEMBL1338398 0.84 ALPL (0.54) POLBTSHRSMN1; SMN2MAPTNPC1
SCHEMBL1339072 0.84 CNR1 (0.38) HSD17B10MAPK8MAPK9CNR1CNR2
SCHEMBL1337046 0.84 GABRG2 (0.42) HSD17B10MAPK8MAPK9MAPK10CNR1
SCHEMBL1338392 0.84 MAPT (0.42) POLBTSHRSMN1; SMN2MAPTNPC1
SCHEMBL1339358 0.83 CNR1 (0.38) HSD17B10MAPK8MAPK9MAPK10CNR1
SCHEMBL1337230 0.82 NPC1 (0.35) NPC1RAB9AL3MBTL1CNR1CNR2
SCHEMBL1338626 0.82 MARS1 (0.49) POLBTSHRSMN1; SMN2MAPTNPC1
SCHEMBL1338687 0.82 GABRA1 (0.39) HSD17B10MAPK8MAPK9MAPK10CNR1
SCHEMBL1338233 0.82 GABRA1 (0.37) HSD17B10MAPK8MAPK9MAPK10CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063061-B2 6-(2-amino-1,3-thiazol-4-yl)-3-(2,4-dichlorophenyl)-1-methyl-1,9-dihydro-2H-pyrido[2,3-b]indol-2-one; affinity for GABAA-receptor-associated omega modulatory sites SANOFI-AVENTIS (FR) 2011-11-22 — — US disclosed
EP-1940840-B1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2010-07-21 — — EP disclosed
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof SANOFI-AVENTIS (FR) 2008-10-23 — — US disclosed
EP-1940840-A1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2008-07-09 — — EP disclosed
WO-2007045758-A1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2007-04-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof CYP11B2, CYP11B1, CYP2D6 POLB 1970/4885TSHR 1472/4885SMN1; SMN2 3153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback